-
[1] M.E. Wolff (Ed.): Burger’s Medicinal Chemistry. Part III, John Willy and sons, New York, 1981, pp. 1205–1271.
-
[2] D. Ratnasinghe, P.J. Daschner, M.R. Anver, B.H. Kasprzak, P.R. Taylor, G.C. Yeh and J.A. Tangrea: “Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is Chemoprevention against multidrug resistance possible”, Anticancer Research, Vol. 21(3C), (2001), pp. 2141–2147.
-
RELATION NAME
-
RELATION NAME
-
[5] G. Singh: “Recent consideration in non steroidal anti-inflammatory drug gastropathy”, Am. J. Med., Vol. 105(1B), (1998), pp. 31S-38S. http://dx.doi.org/10.1016/S0002-9343(98)00072-2
-
RELATION NAME
-
[7] M. Schattenkirchner: “An updated safety profile of etodolac in several thousand patients”, Eur. J. Rheumatol. Inflamm., Vol. 10, (1990), pp. 56–65.
-
[8] H.A. Friendel, H.D. Langtry and M.M. Buckley: “Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic disease”, Drugs, Vol. 45, (1993), pp. 131–156.
-
[9] G.K. Mcevoy (Ed.): AHFS drug information, American society of hospital pharmacists Inc., Bethesda, 1992, pp. 1041–1126.
-
RELATION NAME